share_log

Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3

Benzinga ·  Mar 9, 2023 06:00

Jefferies analyst Kelly Shi downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Underperform and lowers the price target from $18 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment